Safety of human albumin based on spontaneously reported serious adverse events

Critical Care Medicine

Volumn 29, Issue 5, 2001, Pages 994-996

  Von Hoegen, Ilka ^a   Waller, Charles ^a  

^a Plasma Protein Therapeutics Association   (Belgium)

Author keywords

Adverse drug reaction reporting systems; Drug therapy; Fluid therapy; Hospital mortality; Hospitals; Human; Pharmacoepidemiology; Postmarketing; Product surveillance; Safety; Serum albumin

Indexed keywords

HUMAN ALBUMIN;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0035011543     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200105000-00021     Document Type: Article

References (10)

1. Human albumin administration in critically ill patients Systematic review of randomised controlled trials
2. Albumin administration in criticai illness: Systematic review of randomised controlled trials
3. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
4. Adverse drug reactions
5. Pharmacovigilance in the pharmaceutical industry
6. Preventing adverse drug events in hospitalized patients
7. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system
8. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: Risks and predictors of underreporting
9. Is reporting rate a good predictor of risks associated with drugs?
10. Hydroxyethyl starch: Safe or not?